Angina refers to chest pain. The chest pains are very common in hospital settings, particularly emergency department. It usually gets triggered by emotional stress, heavy meals with indigestion, smoking, and sudden exposure to very hot or cold temperatures. Cardiovascular diseases (CVDs) are the major cause of death and disability, worldwide. An estimated 30% of global deaths are due to CVDs, which include nearly 18 million people worldwide. As per the Nesia Foundation Hospital, globally, about 14.2 million people, between the age group 30 and 69 years, die prematurely from lifestyle disorders. Further, as per the Gilead report, in collaboration with the American College of Cardiology, each year, about 13 million US citizens have coronary artery disease and, among them, 9 million have chest pain. These lead to demand for several beta blockers in combination therapies, nitrate-based drugs, and other calcium channel antagonists.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and status of clinical trials across major regions of the world are provided, with data obtained from multiple sources. The report also comprises of a list of key sponsors having pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated, to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation, by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation, by Status
7.6 Other Statuses
8. Pipeline Therapeutic Assessment (Infographic Charts and Brief description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence